Medicare Drug Payment Changes Should Be ‘Physician-Driven’ – Former Official Blum
This article was originally published in The Pink Sheet Daily
Executive Summary
Former CMS Deputy Administrator Jonathan Blum urges agency to 'build support, build consensus and then test' Part B reforms.
You may also be interested in...
Happy Holidays: ‘Most Favored Nation’ Rule Effective Date Likely To Be Delayed
Either through the courts or a postponement by the Trump administration itself, the Medicare Part B rule seems destined to remain dormant instead of going into effect in January as scheduled.
Oncologists Move Against Medicare Part B Drug Payment, Pricing ‘Attacks’
Remember what happened the last time physician groups opposed federal efforts to curtail Medicare spending on Part B drugs?
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.